Rallybio (NASDAQ:RLYB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Rallybio (NASDAQ:RLYB) from a hold rating to a buy rating in a research note released on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a research note on Wednesday, August 5th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Rallybio Price Performance

RLYB opened at $17.00 on Friday. The business has a fifty day simple moving average of $16.11 and a 200 day simple moving average of $11.93. Rallybio has a 1 year low of $3.67 and a 1 year high of $17.57. The company has a market capitalization of $90.27 million, a PE ratio of -3.92 and a beta of -0.90.

Rallybio (NASDAQ:RLYB) last posted its earnings results on Thursday, August 6th. The company reported ($1.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.19. Rallybio had a negative return on equity of 40.53% and a negative net margin of 911.07%.

Institutional Trading of Rallybio

Several large investors have recently modified their holdings of the stock. XTX Topco Ltd raised its stake in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares in the last quarter. Susquehanna International Group LLP grew its stake in Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares in the last quarter. Geode Capital Management LLC grew its stake in Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares in the last quarter. Citadel Advisors LLC increased its holdings in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares during the period. Finally, BlackRock Inc. raised its position in shares of Rallybio by 73.5% in the 2nd quarter. BlackRock Inc. now owns 30,332 shares of the company’s stock valued at $485,000 after buying an additional 12,846 shares in the last quarter. 90.34% of the stock is owned by institutional investors and hedge funds.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.